Merz Aesthetics has secured FDA clearance for Ultherapy PRIME on knee skin laxity, extending the platform's non-surgical lifting footprint beyond the face and neck. The indication leverages PRIME's core advantage—real-time ultrasound visualization during treatment—to guide energy delivery and ensure consistent collagen remodeling in a notoriously difficult anatomical zone.
Devices & Tech
Ultherapy PRIME Clears FDA for Knee Skin Laxity
Merz expands the first real-time ultrasound platform into a new body-contouring indication.
First and only FDA-cleared ultrasound with real-time visualization for non-surgical skin lifting.
Knee laxity remains underserved in most practices. The area is prone to skin laxity post-weight loss and aging, yet few devices deliver predictable results without invasive surgery. PRIME's ability to visualize tissue depth and energy penetration in real time addresses that gap. The clearance positions Merz to capture a secondary revenue stream in body contouring without requiring new hardware investment from practices already running the system.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.